Duaklir Pressair is a prescription drug approved by the Food and Drug Administration (FDA) as long-term maintenance treatment for airflow obstruction in people with chronic obstructive pulmonary disease (COPD). Duaklir Pressair is a combination drug composed of Aclidinium bromide and Formoterol fumarate.
Aclidinium bromide is a long-acting muscarinic antagonist (LAMA). Formoterol fumarate is a long-acting beta2-adrenergic agonist (LABA). Both drugs are bronchodilators. Both drugs are believed to work by relaxing and dilating the airways, making it easier to breathe.
How do I take it?
Duaklir Pressair is taken twice daily.
Duaklir Pressair comes as an inhaler.
The FDA-approved label for Duaklir Pressair lists common side effects including upper respiratory tract infections, headaches, back pain, cough, sinusitis, tooth abscesses, insomnia, dizziness, dry mouth, joint pain, muscle spasms, and musculoskeletal pain.
Rare but serious side effects listed for Duaklir Pressair include an increased risk for asthma-related death, worsening of glaucoma, and worsening of urinary retention.
For more details about this treatment, visit:
Duaklir Pressair – Circassia
Duaklir Pressair – RX List